

BES-1001

A drug-free and non-invasive portable device for the treatment of nasal congestion and related pain

Breathe
again

FACTS & FIGURES

Nasal congestion & related pain

20% of the global population

suffers from chronic nasal congestion, such as **Chronic Rhinosinusitis** and **Allergic Rhinitis** patients, leading to constant **discomfort, pain** and **fatigue** and significantly affecting quality of life

1/3 of patients

with chronic sinus disease develop lower airway dysfunction¹⁻³

Chronic use of decongestants and corticosteroids are associated with

limited efficacy & safety concerns

The **societal burden** of chronic nasal congestion can be

>\$10,000
/patient /year⁴⁻⁵

1. Guillemany et al., Allergy (2009)

2. Kelemence et al., COPD (2011)

3. Lee et al., Allergy Asthma Immunol Res. (2014)

4. Orlandi et al., Int Forum Allergy Rhinol. (2016)

5. Wise et al., Int Forum Allergy Rhinol. (2020)

Presenting BES-1001


BES-1001 is a Swiss-made handheld device with a sleek design that is easy to handle anywhere by anyone; it is connected, reusable and rechargeable.

The device works by using patented and automated Precisely Modulated Acoustic Energy (PMAE) to stimulate the clearance of mucus and increase the nitric oxide levels in the nasal and sinusal cavities, reducing inflammation and alleviating facial pain or pressure.



How to use BES-1001

- Place device head on cheekbone; treatment starts and ends automatically
- Use alone (as monotherapy) or in combination with other medications



Clinical evidence so far


showing promising results



sinus oscillation
during treatment



better sinus
ventilation



faster mucociliary
transport time

BES-1001 Stage of development

- Two PCT patent applications recently filed (2019)
- Design Protection granted in EU and non-EU
- Devices manufactured; safety, risk and performance tested
- PoC clinical study scheduled for Q1 2023
- Commercialisation through partnership as early as 2H 2024
- CE mark (EU) and FDA (US) certifications anticipated early 2024
- Annual peak sales potential well above CHF 135 MN in 7MM

7MM = 7 Major Markets



BioEleSonic Technology Platform

target additional potential indications based on PMAE therapy and IP

Primary Ciliary
Dyskinesia
2.3M

Headache*
75.5M

Obstructive
Sleep Apnoea
16.4M

*(Migraine & Tension-Type Headache)

Figures refer to patients eligible for BES-1001 treatment in the EU4, UK, US and Japan